title: Factor VIII and fibrinogen recovery in plasma after Theraflex methylene blue-treatment: effect of plasma source and treatment time.
abstract: BACKGROUND
  The quality of fresh-frozen plasma is affected by different factors. Factor VIII is sensitive to blood component storage processes and storage as well as pathogen-reduction technologies. The level of fibrinogen in plasma is not affected by the collection processes but it is affected by preparation and pathogen-reduction technologies.
  
  
  METHODS
  The quality of plasma from whole blood and apheresis donations harvested at different times and treated with a pathogen-reduction technique, methylene blue/light, was investigated, considering, in particular, fibrinogen and factor VIII levels and recovery.
  
  
  RESULTS
  The mean factor VIII level after methylene blue treatment exceeded 0.5 IU/mL in all series. Factor VIII recovery varied between 78% and 89% in different series. The recovery of factor VIII was dependent on plasma source as opposed to treatment time. The interaction between the two factors was statistically significant. Mean levels of fibrinogen after methylene blue/light treatment exceeded 200 mg/dL in all arms. The level of fibrinogen after treatment correlated strongly with the level before treatment. There was a negative correlation between fibrinogen level before treatment and recovery. Pearson's correlation coefficient between factor VIII recovery and fibrinogen recovery was 0.58.
  
  
  CONCLUSIONS
  These results show a difference in recovery of factor VIII and fibrinogen correlated with plasma source. The recovery of both factor VIII and fibrinogen was higher in whole blood plasma than in apheresis plasma. Factor VIII and fibrinogen recovery did not appear to be correlated.
authors.affiliation: Belgian Red Cross, Blood Service, Suarlée, Belgium, Germany.
authors.forename: André
authors.initials: A
authors.lastname: Rapaille
authors.affiliation: Macopharma International GmbH, Langen, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Reichenberg
authors.affiliation: Belgian Red Cross, Blood Service, Suarlée, Belgium, Germany.
authors.forename: Tome
authors.initials: T
authors.lastname: Najdovski
authors.affiliation: Belgian Red Cross, Blood Service, Suarlée, Belgium, Germany.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Cellier
authors.affiliation: Belgian Red Cross, Blood Service, Suarlée, Belgium, Germany.
authors.forename: Nicolas
authors.initials: N
authors.lastname: de Valensart
authors.affiliation: Belgian Red Cross, Blood Service, Suarlée, Belgium, Germany.
authors.forename: Véronique
authors.initials: V
authors.lastname: Deneys
mesh_terms: D001781:Blood Component Removal / Q000379:methods; D001793:Blood Preservation; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005169:Factor VIII / Q000032:analysis*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D008297:Male; D008751:Methylene Blue / Q000494:pharmacology*; D010949:Plasma / Q000737:chemistry* / Q000378:metabolism; D013997:Time Factors
chemical_list: D004791:Enzyme Inhibitors; C078147:F8 protein, human; D005169:Factor VIII; D005340:Fibrinogen; D008751:Methylene Blue